RPRX Stock and Options Trade Setup — Royalty Pharma
Nasdaq · Healthcare (Pharmaceutical Royalties) · Low-to-moderate options liquidity · Large cap · ~$14B
Royalty Pharma has built the most capital-efficient business model in biopharma: it acquires the revenue-stream rights to drugs that have already survived clinical development, eliminating binary trial risk while capturing the commercial upside. The portfolio of 35+ royalty-generating products (including Imbruvica, Trikafta, Nurtec, Tremfya) provides diversification that no single-drug biotech can match. The business is structurally designed for compounding: royalties require zero CAPEX to maintain, generating free cash flow conversion above 95%, and Royalty Pharma reinvests that cash into new royalty acquisitions at 8-12% IRR on a risk-adjusted basis. The royalty model is growing in appeal to cash-constrained biotech founders who prefer selling royalty streams over equity dilution, expanding the deal sourcing universe. At 11x forward FCF, RPRX is priced like a slow-growth utility when it is in reality a capital-compounding machine with a 35+ drug diversified cash flow base.
Score History & Signal Changelog
Preview dataThis page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.
Signal Breakdown
Today's Trade Card
Options Profile
Risks & Fundamentals
Every setup carries risk. Here's what could move RPRX against you, plus the key stats that frame any position.
- 1.Drug pricing reform (IRA Medicare negotiation expansion) reducing royalty stream revenue on high-volume drugs
- 2.Key royalty expiration risk — Imbruvica (AbbVie) royalties declining as biosimilar competition increases
- 3.Competition from Blackstone Royalties, BioPharma Credit, and healthcare-focused funds bidding up acquisition prices
RPRX Options Setup — Frequently Asked Questions
Is RPRX a good options trade today?+
Royalty Pharma (RPRX) currently has an Amora Edge Score of 68/100, ranking it top 22% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.
What is RPRX's win rate on Stoptions.ai setups?+
RPRX's historical win rate on closed Stoptions setups is 64%. Win rate is calculated as the percentage of past RPRX trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.
What strike and expiry does Stoptions.ai suggest for RPRX?+
The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.
How often is the RPRX setup updated?+
Every 72 hours we refresh RPRX's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If RPRX drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.
What does the Amora Edge Score measure for RPRX?+
The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to RPRX: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is RPRX outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. RPRX currently scores 68.
How does RPRX compare to other Healthcare (Pharmaceutical Royalties) setups?+
RPRX's sector rank and percentile against other Healthcare (Pharmaceutical Royalties) tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Healthcare (Pharmaceutical Royalties) Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.
Educational content only — not personalized investment advice. Options carry substantial risk.
Get a Friday recap including setups like RPRX.
Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.
No spam. One email Friday afternoon. Unsubscribe in one click.